

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JW (Cayman) Therapeutics Co. Ltd

藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of JW (Cayman) Therapeutics Co. Ltd (the “**Company**”) dated May 21, 2023 in relation to the Vector Supply Agreement and the transactions contemplated thereunder (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, further details of the Vector Supply Agreement and the transactions contemplated thereunder and a notice convening the EGM will be despatched to the Shareholders on or before May 26, 2023.

As additional time is required for the Company to prepare and finalize certain information to be included in the Circular, it is expected that the despatch date of the Circular will be postponed to a date falling on or before June 12, 2023.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Yiping James Li
Chairman

Shanghai, PRC, June 2, 2023

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yiping James Li as Chairman and executive Director, Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr. Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive Directors, and Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho and Dr. Debra Yu as independent non-executive Directors.

* For identification purpose only